Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate
This article was originally published in The Pink Sheet Daily
Executive Summary
Better-than-expected response rates in pivotal Hodgkin lymphoma trial have company and the Street hopeful for an easy regulatory review.
You may also be interested in...
Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.
Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.
Full Data For Seattle Genetics’ Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
Seattle Genetics and partner Takeda are revising their regulatory strategy and will file their antibody drug conjugate SGN-35 in the first quarter of 2011 for both Hodgkin's lymphoma and anaplastic large cell lymphoma, following a positive reception for their pivotal data at the American Society of Hematology annual meeting.